SERB Pharmaceuticals
SERB Pharmaceuticals is a global pharmaceutical group focused on the development, manufacture, and distribution of essential and emergency medicines, including treatments for rare diseases and medical countermeasures for chemical, biological, radiological, and nuclear (CBRN) threats. Operating across the US, Europe, the Middle East, and Australia, SERB delivers a portfolio encompassing antidotes, biologics, and specialty emergency care products while supporting independent and collaborative research initiatives in critical care and rare disease management.
Industries
N/A
Products
Comprehensive range of antidotes, medical countermeasures, and critical care pharmaceutical products supplied worldwide, including for chemical, biological, radiological, and nuclear threats.
Therapeutic biologics produced using a polyclonal antibody manufacturing platform for use in indications such as envenomations and poisonings.
Pharmaceutical antidotes and treatments for chemical, biological, radiological, and nuclear emergencies, enabling preparedness and response for national and organizational stakeholders.
Comprehensive range of antidotes, medical countermeasures, and critical care pharmaceutical products supplied worldwide, including for chemical, biological, radiological, and nuclear threats.
Therapeutic biologics produced using a polyclonal antibody manufacturing platform for use in indications such as envenomations and poisonings.
Pharmaceutical antidotes and treatments for chemical, biological, radiological, and nuclear emergencies, enabling preparedness and response for national and organizational stakeholders.
Services
Funding to healthcare organizations to support independent educational programs, patient advocacy, and healthcare-related education, with defined application criteria and compliance requirements.
Funding provided to support data analysis, medical writing, and research fellowships for independent healthcare research.
Support for independent research studies led by healthcare professionals, including provision of pharmaceutical products and/or financial support, subject to scientific and ethical review.
Funding to healthcare organizations to support independent educational programs, patient advocacy, and healthcare-related education, with defined application criteria and compliance requirements.
Funding provided to support data analysis, medical writing, and research fellowships for independent healthcare research.
Support for independent research studies led by healthcare professionals, including provision of pharmaceutical products and/or financial support, subject to scientific and ethical review.
Expertise Areas
- Critical care pharmaceuticals
- Rare disease therapeutics
- Medical countermeasure development
- Antidote research and supply
Key Technologies
- Polyclonal antibody platform
- Pharmaceutical formulation
- Biologics manufacturing
- Contract manufacturing
Key People
Chairman
Chief Executive Officer
Chief Financial Officer
Executive VP, Chief Commercial Officer Europe & International
Executive VP, Chief Commercial Officer US
Chief Medical Officer
Chairman
Chief Executive Officer
Chief Financial Officer
Executive VP, Chief Commercial Officer Europe & International
Executive VP, Chief Commercial Officer US
Chief Medical Officer
News & Updates
Completed acquisition of Y-mAbs Therapeutics, expanding the company's portfolio in antibody-based cancer therapeutics.
Expanded emergency care portfolio with the acquisition of iloprost IV for severe frostbite.
Strengthened medical countermeasures offering with the global acquisition of Reactive Skin Decontamination Lotion.
Acquired two products for rare diseases, broadening the company's specialty and rare disease portfolio.
Acquired rights to Xermelo for carcinoid syndrome diarrhoea, expanding product reach outside US and Japan.
Received EU approval for Voraxaze (glucarpidase) as rescue therapy for high-dose methotrexate toxicity.
Completed acquisition of Y-mAbs Therapeutics, expanding the company's portfolio in antibody-based cancer therapeutics.
Expanded emergency care portfolio with the acquisition of iloprost IV for severe frostbite.
Strengthened medical countermeasures offering with the global acquisition of Reactive Skin Decontamination Lotion.
Acquired two products for rare diseases, broadening the company's specialty and rare disease portfolio.
Acquired rights to Xermelo for carcinoid syndrome diarrhoea, expanding product reach outside US and Japan.
Received EU approval for Voraxaze (glucarpidase) as rescue therapy for high-dose methotrexate toxicity.